Loading organizations...
§ Private Profile · Malvern, PA, USA
Venatorx Pharmaceuticals is a technology company.
Venatorx Pharmaceuticals develops novel anti-infective agents to combat multi-drug-resistant bacterial infections. Its pipeline features small molecule therapeutics, including beta-lactamase inhibitors like cefepime-taniborbactam and ceftibuten-ledaborbactam. The company focuses on overcoming bacterial resistance, providing new options for severe infections where current solutions fail.
Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., founded Venatorx Pharmaceuticals in 2010. This team previously collaborated at Protez Pharmaceuticals, gaining shared insight into antimicrobial resistance. Their collective experience led to establishing the company, dedicated to advancing innovative anti-infective therapies.
Venatorx Pharmaceuticals' therapies address patients suffering from serious multi-drug-resistant bacterial infections, offering critical new options where existing antibiotics fail. The company’s vision combats the global public health crisis of antibiotic resistance by delivering effective, life-saving medicines. They aim to restore antibiotic efficacy for future generations.
Venatorx Pharmaceuticals has raised $95.4M across 4 funding rounds.
Venatorx Pharmaceuticals has raised $95.4M in total across 4 funding rounds.
Venatorx Pharmaceuticals has raised $95.4M across 4 funding rounds. Most recently, it raised $34.0M Series C in April 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2022 | $34M Series C | — | AMR Action Fund, Boehringer Ingelheim Venture Fund, Vivo Capital | Announced |
| Jan 4, 2018 | $16M Venture Round | Defense Threat Reduction Agency | — | Announced |
| Jul 1, 2017 | $42M Series B | Versant Ventures | General Atlantic, Shelley CHU, Brett Zbar | Announced |
| Dec 6, 2013 | $3.4M Venture Round | — | — | Announced |
Venatorx Pharmaceuticals has raised $95.4M in total across 4 funding rounds.
Venatorx Pharmaceuticals's investors include AMR Action Fund, Boehringer Ingelheim Venture Fund, Vivo Capital, Defense Threat Reduction Agency, Versant Ventures, General Atlantic, Shelley Chu, Brett Zbar.
VenatoRx Pharmaceuticals is a private, clinical-stage biopharmaceutical company specializing in the discovery and development of novel anti-infectives to combat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections.[1][2][3] Its lead product, VNRX-5133, is an injectable beta-lactamase inhibitor (BLI) combined with cefepime, targeting carbapenem-resistant pathogens like CRE and CRPA, bioterror agents, and polymicrobial infections, with potential as a best-in-class broad-spectrum treatment.[1] The company serves patients with severe infections, healthcare providers, and global health organizations, addressing the critical problem of antibiotic resistance where existing therapies fail.[1][2][3] Backed by $54.9M in funding from investors like Versant Ventures, Abingworth, Foresite Capital, and grants from NIAID, Wellcome Trust, CARB-X, and DTRA, VenatoRx maintains a preclinical pipeline including oral BLIs, novel PBP inhibitors, and antivirals, with recent commercial deals like the Menarini Group agreement for cefepime-taniborbactam in 96 countries signaling growth momentum.[1][2]
Founded in 2010 in Malvern, Pennsylvania, by three antimicrobial R&D veterans, VenatoRx started as a virtual company with seed funding from a multi-million-dollar, three-year NIH grant to pursue novel molecules against drug-resistant infections.[2][3] The founders leveraged their pharma expertise to target emerging beta-lactamase resistance, evolving from preclinical focus to a clinical-stage operation with a 50-person team and five pipeline projects.[3] Early traction came from non-dilutive grants and private investments, enabling nimble adaptation to MDR threats; pivotal moments include advancing VNRX-5133 into combination development and securing partnerships amid intensifying global resistance.[1][3]
VenatoRx rides the global antimicrobial resistance (AMR) crisis, where MDR bacteria like CRE and CRPA cause millions of deaths annually, driven by overuse and innovation gaps in anti-infectives.[1][3] Timing is critical amid post-pandemic bioterror concerns and WHO priorities, with market forces like government incentives (e.g., CARB-X) and pull programs favoring novel agents over generics.[1][3] The company influences the ecosystem by sharing AMR surveillance data via Vivli, advancing preclinical platforms for new antibiotics, and forging commercialization pacts that expand access in underserved regions.[2][4] As a biotech leader, it counters Big Pharma's retreat from antibiotics, bolstering the pipeline against "superbugs" and viral threats.[3]
VenatoRx is poised for Phase 3 trials and regulatory approvals of cefepime/VNRX-5133, with Menarini commercialization accelerating revenue in 2026+ across 96 countries.[2] Pipeline expansion into oral therapies and antivirals will capitalize on rising AMR trends, bolstered by sustained grant funding and investor support amid escalating resistance waves.[1][3] Its influence may grow through more global partnerships and data platforms, potentially reshaping MDR treatment standards—positioning it as a key player in an ecosystem desperate for innovation, much like its origins tackling unmet resistance needs.[1][2]